Australian Male Contraceptive Draws Little Drug Maker Interest
This article was originally published in PharmAsia News
Australian researchers say they have developed a male injectable contraceptive as effective as the pill has been for women. Trials show the testosterone-based drug that suppresses sperm output to be as much as 95 percent effective when taken four times a year. But a leading researcher said pharmaceutical companies that were involved in development have withdrawn from the project and others have shown little interest in it. The research also has drawn little interest and funding from the Australian government. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.